Given the phenotypic outcome of accumulated nuclear cyclin D1/CDK4 complexes, further mechanistic investigation is required for development of novel therapeutic strategies to promote tumor cell death in cancers overexpressing cyclin D1. The gene discussed is CDK4; the disease is neoplasm.